1.60Open1.55Pre Close49 Volume138 Open Interest10.00Strike Price6.78KTurnover77.83%IV3.56%PremiumDec 20, 2024Expiry Date0.96Intrinsic Value100Multiplier24DDays to Expiry0.39Extrinsic Value100Contract SizeAmericanOptions Type0.7157Delta0.1535Gamma7.69Leverage Ratio-0.0162Theta0.0043Rho5.50Eff Leverage0.0096Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet